Sana Biotechnology Q2 2026: $160.5M Cash, Runway into Mid-2027, and Pipeline Momentum
SANA sits 35% above its 52-week low of $2.61.
Summary
Sana Biotechnology posted Q2 2026 financials with $160.5M in cash, a $110.8M H1 net loss, and a runway extended into mid-2027 after raising $93.3M. Pipeline progress continues, with SC451 and SG293 trials on track to start as early as this year.
Key Events · Earnings and Guidance · SANA
-
Q2 2026 Financial Results
The net loss reached $63.6M ($0.22/share) for Q2 and $110.8M ($0.39/share) for H1 2026. As of June 30, 2026, cash stood at $160.5M, which is expected to fund operations into mid-2027.
-
Financing Activities
During Q2 2026, $93.3M in net proceeds were raised through ATM sales and a $25.0M equity investment from Mayo Clinic, extending the cash runway.
-
Pipeline Progress
IND filings and clinical trial starts for SC451 (type 1 diabetes) and SG293 (non-Hodgkin lymphoma) remain on track for as early as this year. Meanwhile, 14-month data for UP421, published in NEJM, showed durable insulin production without immunosuppression.
-
Mayo Clinic Collaboration
A strategic collaboration with Mayo Clinic aims to accelerate SC451 development, supported by a $25.0M equity investment.
Analysis · SANA · Life Sciences
Sana Biotechnology's Q2 2026 earnings paint a going-concern picture, with $160.5 million in cash and a net loss of $110.8 million for the first half of 2026. The quarter brought $93.3 million in fresh capital through the ATM facility and a $25 million equity investment from Mayo Clinic, pushing the runway into mid-2027. While the cash buffer offers near-term stability, the persistent losses and dependence on dilutive financing remain critical risks. Pipeline updates—including progress toward clinical trials for SC451 and SG293—are encouraging, but the financials underscore the urgency of hitting value-creating milestones before the cash runs low.
At the time of this filing, SANA was trading at $3.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.61 to $6.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.